注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Kiora Pharmaceuticals Inc是一家临床阶段的制药公司。该公司专注于开发和商业化治疗眼科疾病的疗法。该公司的管线包括三个候选产品:KIO-101、KIO-301和KIO-201。该公司的主导产品KIO-301是一种潜在的视力恢复小分子,旨在恢复患有遗传性和与年龄相关的退行性视网膜疾病患者的视力。KIO-101是一种非甾体、免疫调节、小分子二氢乳清酸脱氢酶(DHODH)抑制剂,专注于类风湿关节炎眼部表现(OPRA)患者。该公司的KIO-201是一种合成的改性透明质酸(HA),能够覆盖眼表,旨在抵抗眼部条件下的降解。该公司的全资子公司包括Jade Therapeutics Inc、Kiora Pharmaceuticals GmbH、Bayon Therapeutics Inc和Kiora Pharmaceuticals Pty Ltd。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Daniel S. Durrie | 73 | 2017 | Member of Scientific Advisory Board |
Paul M. Karpecki | 56 | 2017 | Member of Scientific Advisory Board |
Victor Perez | - | 2018 | Member of Scientific Advisory Board |
Aron Shapiro | 45 | 2021 | Director |
Brian M. Strem | 43 | 2021 | President, CEO & Director |
Praveen Tyle | 63 | 2008 | Independent Chairman of the Board |
Kenneth L. Gayron | 53 | 2021 | Independent Director |
David A. Hollander | 49 | 2021 | Independent Director |
Erin Parsons | 47 | 2022 | Non-Employee Independent Director |
Charlie Wykoff | - | - | Member of Scientific Advisory Board |
Francis Mah | - | - | Member of Scientific Advisory Board |
Allen C. Ho | - | - | Member of Scientific Advisory Board |
Christine Kay | - | - | Member of Scientific Advisory Board |
Carmine N. Stengone | 47 | 2023 | Independent Director |
Russell Van Gelder | - | - | Member of Scientific Advisory Board |
Mark Pennesi | - | 2023 | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核